International drug companies are threatening to remove medicines from the market if Australia doesn’t offer them a better price. Here’s what’s at stake.
Articles on Pharmaceutical companies
Displaying 1 - 20 of 30 articles
Vaccine development can be really expensive, and there’s limited commercial return.
Some industry-funded clinical trials show signs of being designed to market drugs rather than to test them for their safety and effectiveness. Detecting these studies remains difficult.
To lower health care costs, the Trump administration will have to wrangle a complex system fraught with competing interests.
Canada has no accreditation or inspection system for research ethics boards for clinical drug trials, and no oversight mechanism for the way that they undertake reviews.
We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.
Pharmaceutical companies have little incentive to sell drugs to countries that can’t afford them. But bargaining together can increase access to vital treatments worldwide.
Harris and Trump have starkly contrasting records on health care. This analysis examines their differing approaches to Medicare, the ACA, drug pricing and other public health efforts.
Canada has a lack of transparency about Big Pharma’s payments to health-care providers and organizations. Disclosure is voluntary, and there’s no central data on even the few companies that do report.
Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
The US PEPFAR initiative has brought HIV medication to millions of people globally. Behind this progress are the activists that pressured politicians and companies to put patients over patents.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
The Medicines Patent Pool was created to promote public health, facilitating generic licensing for patented drugs that treat diseases predominantly affecting low- and middle-income countries.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
Western pharmaceutical companies can’t stop supplying essential medicines to Russia, but they can cease other business.
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
Listen to experts discuss the business practices of pharmaceutical companies in The Conversation Weekly podcast.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
If no action is taken to address antibiotic resistance, infections from multidrug-resistant bacteria could cause 10 million deaths each year by 2050.
Top contributors
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor of Philosophy, Binghamton University, State University of New York
-
Senior Research Manager, University of Sydney and Honorary Assistant Professor, Bond University
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Associate Lecturer, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Professeur des Universités, IAE Paris – Sorbonne Business School
-
Chen Su Lan Centennial Professor in Medical Ethics, National University of Singapore; Distinguished Visiting Professor in Law, University of Melbourne; Uehiro Chair in Practical Ethics, The University of Melbourne
-
Professor of Biochemistry and Biomedical Sciences, McMaster University
-
Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
-
Associate Professor of History, Florida International University
-
Professor of Intellectual Property Law, City St George's, University of London
-
Adjunct Lecturer, School of Pharmacy, University of Sydney
-
Henry Baldwin Professorial Research Fellow in Health System Sustainability, University of Tasmania